Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects
AssigneeStryker Corporation
InventorsDavid C. Rueger, Marjorie M. Tucker
Life of this patent
Estimating the term…
Abstract
Disclosed herein are improved osteogenic devices and methods of use thereof for repair of bone and cartilage defects. The devices and methods promote accelerated formation of repair tissue with enhanced stability using less osteogenic protein than devices in the art. Defects susceptible to repair with the instant invention include, but are not limited to: critical size defects, non-critical size defects, non-union fractures, fractures, osteochondral defects, subchondral defects, and defects resulting from degenerative diseases such as osteochondritis dessicans.
Claims34
A method for inducing local bone or cartilage formation, comprising the step of providing to a defect site a device comprising:
- (a) a bone morphogenetic protein selected from the group consisting of OP1, OP2, OP3, BMP2, BMP3, BMP4, BMP5, BMP6, BMP9, BMP10, BMP11, BMP12, BMP15, BMP16, DPP, Vgl, 60A protein, GDF-1, GDF3, GDF5, GDF6, GDF7, GDF8, GDF9, GDF10 and GDF11;
- (b) a matrix selected from the group consisting of collagen, apatites, hydroxyapatites, tricalcium phosphate, and admixtures thereof;
- and
- (c) a binding agent selected from the group consisting of cellulosic agents and salts thereof wherein said binding agent has a degree of substitution of 0.65-0.90 and a viscosity of about 10-200 cP at a 4% (w/v) concentration of said binding agent.
A method for inducing local bone and cartilage formation, comprising the step of providing to a defect site a device comprising:
- (a) a bone morphogenetic protein comprising an amino acid sequence having at least 70% homology with the C-terminal 102-106 amino acids, including the conserved seven cysteine domain, of human OP 1;
- (b) a matrix selected from the group consisting of collagen, apatites, hydroxyapatites, tricalcium phosphate, and admixtures thereof;
- and
- (c) a binding agent selected from the group consisting of cellulosic agents and salts thereof;
- wherein said binding agent has a degree of substitution of 0.65-0.90 and a viscosity of about 10-200 cP at a 4% (w/v) concentration of said binding agent;
- and
- wherein said bone morphogenetic protein is capable of inducing repair of endochondral bone when implanted together with a matrix in a mammal.
A method for inducing local bone or cartilage formation, comprising the step of providing to a defect site a device comprising:
- (a) at least approximately 1.25 mg of OP-1;
- and
- (b) at least approximately 180 mg of carboxymethylcellulose per 1000 mg of collagen matrix;
- wherein said carboxymethylcellulose has a degree of substitution of 0.65-0.90 and a viscosity of about 10-200 cP at a 4% (w/v) concentration of said carboxymethylcellulose.
A method for inducing local bone or cartilage formation, comprising the step of providing to a defect site a device comprising:
- (a) OP-1;
- (b) collagen matrix;
- and
- (c) carboxymethylcellulose having a degree of substitution of 0.65-0.90 and a viscosity of about 10-200 cP at a 4% (w/v) concentration of said carboxymethylcellulose.
Dependencies are inferred from the claim text.